A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis
Authors
Nkechi Azie
Paul Nyirjesy (ORCID: https://orcid.org/0000-0001-5309-2971)
Ryan Sobel (ORCID: https://orcid.org/0000-0002-1959-2910)
A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis
Nkechi Azie, Paul Nyirjesy, Ryan Sobel, Oluwatosin Goje et al.
Citations
7 citations
Journal
American Journal of Obstetrics and Gynecology
Topics
Reproductive tract infections research
Field-Weighted Citation Impact (FWCI)
8.28
article
A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis
Nkechi Azie, Paul Nyirjesy, Ryan Sobel, Oluwatosin Goje, Jack D. Sobel, David Angulo
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
American Journal of Obstetrics and GynecologyVol. 233(6)
Institutions
Cleveland Clinic (US), Thomas Jefferson University (US), Wayne State University (US), Cleveland Foundation (US), Scynexis (United States) (US)